Application of KDM6B as target spot in screening of drugs for targeted treatment of breast cancer

• Main Authors: WANG WENQIAN, HUA CHUNYAN, YU ANNI
• Format: Patent
• Language: Chinese; English
• Published: 26.04.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention discloses application of KDM6B as a target spot in screening of drugs for targeted therapy of breast cancer. The application comprises one or more of (A)-(C): (A) low expression of KDM6B affects proliferation and apoptosis of breast cancer cells; (B) the low expression of KDM6B is closely related to the stemness characteristic of breast cancer cells; (C) the low expression of the KDM6B affects the breast cancer immune microenvironment by regulating the expression of chemotactic factors and cytokines; the drug is an overexpression plasmid for enhancing KDM6B expression so as to reverse breast cancer development; kDM6B expression is used as an EZH2 inhibitor GSK126 in clinical application. According to the technical scheme, low expression of the KDM6B promotes growth of breast cancer cells, enhances dryness of the breast cancer cells and mediates formation of a breast cancer immunosuppression microenvironment; the overexpression of the KDM6B gene can inhibit proliferation of breast cancer cells, r